Ligneous Conjunctivitis Clinical Trial
Official title:
Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population
The purpose of this protocol is to provide compassionate use of Kedrion Human Plasminogen Ophthalmologic Drops to an expanded population of patients diagnosed with ligneous conjunctivitis associated with type I Plasminogen deficiency until product licensure, and/or until a new clinical trial is available and the patients in treatment under Expanded Access are eligible to participate in the new trial.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01554956 -
Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients
|
Phase 2/Phase 3 |